New epigenetic drug against Mantle Cell Lymphoma A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical ResearchInstitute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a...
Tag: <span>Leukemia</span>
Post
Exploring a novel bispecific technology engineered to fight a number of cancers
For patients with B-cell cancers like acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) that don’t respond to or relapse after chemotherapy, prognosis remains poor, and nearly half of patients will lose the fight against their disease.1 However, the field of cancer care is progressing rapidly, and additional options beyond chemotherapy have been made available to...
Post
Protein responsible for Leukemia’s aggressiveness identified
(Boston)–Researchers have identified a protein critical for the aggressiveness of T-cell leukemia, a subtype of leukemia that afflicts children and adults. The identification of ubiquitin-fusion degradation 1 (UFD1) allows for better understanding what causes leukemia to progress and become highly aggressive and treatment-resistant, and may lead to a new treatment for this type of cancer. Leukemia...
Post
Vitamin C Depletion Accelerates Leukemia in Mice
High levels of vitamin C absorbed by blood-forming stem cells are important for their normal development. Ascorbate, also known as vitamin C, plays a key role in determining whether blood-forming stem cells will become cancerous, according to a study of cell cultures and mice published today (August 21) in Nature. Both human and mouse hematopoietic stem...
Post
Clinical trial suggests new cell therapy for relapsed leukemia patients
A Wright’s stained bone marrow aspirate smear from a patient with precursor B-cell acute lymphoblastic leukemia. A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at the Stanford University School...
Post
Leukemia: Cancer cells killed off with diabetes drug
Scientists may have found an innovative way to kill off cancer cells in acute myeloid leukemia, all the while preserving and regenerating healthy red blood cells. Researchers may have found a way to suppress leukemic cells (shown here) while preserving healthy red blood cells. The new study was carried out by researchers from the McMaster Stem Cell...
Post
Inhibitors support immune therapy for leukemia
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University...
Post
Vitamin C may stop leukemia from progressing
Since the 1970s, researchers have taken an interest in high-dose vitamin C and its therapeutic potential for treating cancer. New research shows how vitamin C might stop leukemic stem cells from multiplying, and thus block some forms of blood cancer from advancing. New research suggests that vitamin C, when administered intravenously, may block leukemic stem...
Post
Scientists discover vitamin C regulates stem cell function, curbs leukemia development
Not much is known about stem cell metabolism, but a new study from the Children’s Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then regulates their function and suppresses the development of leukemia. “We have known for a while that people...
Post
Discovery points to drugs that would ‘short-circuit’ deadly leukemia
Researchers at St. Jude Children’s Research Hospital have discovered that survival of a particularly aggressive form of acute myeloid leukemia (AML) depends on production of a small molecule called heme that is a kind of molecular “battery.” The researchers said discovery of this vulnerability points the way to new targeted drug therapies that block heme...